Our Offering
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual and Sustainability Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Our Offering
Corporate
Biologics
Mammalian
Microbial
ADCs / Bioconjugates
Drug Product
mRNA / LNP
Expression Technologies
Small Molecules
Drug Substance (API)
Particle Engineering
Drug Product
Cell & Gene
Process Development
cGMP manufacturing
Allogeneic
Autologous
Viral Vectors
Bioscience Products
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Our Company
Corporate
About Us
Purpose and Strategy
Leadership
History
Locations
Site Tours
Partnering with Us
Events
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
Podcast
Journalist Inquiries
Investor Relations
Shareholder Information
Agenda and Events
Financial Reporting
Annual and Sustainability Report
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Performance
People
Planet
Community
Global Quality
Responsible Sourcing
Careers
Corporate
Overview
Life at Lonza
What We Offer
Career Stories
Job Search
Join Our Talent Community
Recruitment Process
Students, Graduates and Apprentices
Contact
Corporate
News Releases
Home
Filter Results
Filter
Filter by:
Offering
Corporate (295)
Cell & Gene (117)
Biologics (92)
Capsules & Health Ingredients (59)
Small Molecules (27)
News Category
General (447)
Partnerships (67)
Financials (65)
New Products (31)
Ad hoc (20)
Acquisitions (19)
New Technologies (10)
Year
2024 (6)
2023 (21)
2022 (37)
2021 (59)
2020 (71)
2019 (89)
2018 (82)
2017 (67)
2016 (65)
2015 (48)
2014 (45)
Language
English (590)
English
X
Showing 1‐10 of 500
Corporate
17 Apr 2024
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion...
Corporate
03 Apr 2024
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will not stand for re-election as Chairman of the Board of...
Corporate
02 Apr 2024
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024 Albert M. Baehny will retire from Lonza...
Corporate
20 Mar 2024
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash
Corporate
26 Jan 2024
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Corporate
26 Jan 2024
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Corporate
06 Nov 2023
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million...
Corporate
17 Oct 2023
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023:...
Biologics
16 Oct 2023
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration...
Biologics
13 Oct 2023
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza's...
Media Advisories
Updates for media on the latest products, offerings and developments across our business.
View all
Cookie Settings